Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/27/24
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference CallGlobeNewsWire • 03/20/24
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer SymposiumGlobeNewsWire • 12/06/23
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer SymposiumGlobeNewsWire • 12/01/23
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 11/13/23
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference CallGlobeNewsWire • 11/06/23
Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical TrialGlobeNewsWire • 08/22/23
Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate CancerGlobeNewsWire • 08/22/23
Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 08/10/23
Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference CallGlobeNewsWire • 08/03/23